Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM) and Nylon product lines for sale...(ill estimate continue anticipates ...),Health

Date:2/26/2009

ill," "estimate," "continue," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the fourth quarter of 2008 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development a
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Angiotech Pharmaceuticals, Inc. - Notice of conference call and webcast
2. Angiotech To Participate In The American Academy Of Ophthalmology (AAO) 2007 Annual Meeting
3. Angiotech to participate in CIBC 18th Annual Healthcare Conference
4. Solos Endoscopy, Inc. Receives Purchase Order from Major Connecticut Hospital for the MammoView(TM)
5. Boston University School of Medicine receives grant
6. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
7. Pharmacyclics Receives Nasdaq Notification
8. ING Run For Something Better Receives Healthy Youth for a Healthy Future Champion Award
9. International Partnership for Microbicides Receives US $130 Million from UK Government and the Gates Foundation
10. Industry Leading Data Quality and Householding Software Receives New Functionality for Enhanced Performance and Speed
11. Oridion Receives FDA 510(k) Clearance for Capnostream(TM)20 Monitor With Integrated Pulmonary Index(TM)